Tuesday, February 22, 2022

CADILAHC

CADILAHC(Cadila Healthcare Limited)

04.02.2022 - Jefferies on CADILA Maintain Hold CMP 407 Target 439(PREV TGT 490)
04.02.2022 - Nomura on CADILA Maintain Buy CMP 407 Target 489
04.02.2022 - MS on CADILA Maintain Overweight CMP 407 Target 543

CLSA ON CADILA HEALTHCARE : 28.05.2021

* Cut rating from BUY to Outperform, Target at Rs 670/share
* A neat 10% beat on Ebitda; large tax writeback drives bigger beat on net profit
* Strong quarter for domestic business but weak print for export sales
* Long-term growth story intact given R&D initiatives; Recent 44% rally and margin pressure to cap significant upside

ERIS

ERIS(Eris Lifesciences Ltd) 18.01.2023 -  Macquarie  on  ERIS Maintain Outperform CMP 625.75 Target 830